Top executive admits that pharmaceutical company Novartis will assess India for additional manufacturing capacity.
According to Vas Narasimhan, worldwide Chief Executive Officer (CEO) of Novartis, the Swiss pharmaceutical giant would assess India to build up its production capacity and technological breakthroughs in the future, if necessary. Over the past five years, Novartis has made over $300 million in India. Novartis’ drug portfolio in India includes both cutting-edge and well-established treatments for cardiovascular, ocular, metabolic, neurological, oncological, respiratory, and organ transplant conditions. One of the few nations in the world where Novartis has a significant presence that spans early research, drug development, technical operations, business services, and commercial activities is India. Although Narasimhan stated that…